Journal of the American Academy of Child & Adolescent Psychiatry
Volume 47, Issue 1 , Pages 9-20 , January 2008

Antipsychotic Use in Children and Adolescents: Minimizing Adverse Effects to Maximize Outcomes

,Accepted 6 September 2007.

REFERENCES 

  1. Olfson M , Blanco C , Liu L , Moreno C , Laje G . National trends in the outpatient treatment of children and adolescents with antipsychotic drugs . Arch Gen Psychiatry . 2006;63:679–685
  2. Cheng-Shannon J , McGough JJ , Pataki C , McCracken JT . Second-generation antipsychotic medications in children and adolescents . J Child Adolesc Psychopharmacol . 2004;14:372–394
  3. Schur SB , Sikich L , Findling RL , et al.   Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY): I. A review . J Am Acad Child Adolesc Psychiatry . 2003;42:132–144
  4. Pappadopulos E , McIntyre JC , Crismon ML , et al.   Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY): II . J Am Acad Child Adolesc Psychiatry . 2003;42:145–161
  5. Correll CU . Real life switching strategies with second-generation antipsychotics . J Clin Psychiatry . 2006;67:160–161
  6. Correll CU , Penzner JB , Parikh UH , et al.   Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents . Child Adolesc Psychiatr Clin N Am . 2006;15:177–206
  7. Sikich L , Hamer RM , Bashford RA , Sheitman BB , Lieberman JA . A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial . Neuropsychopharmacology . 2004;29:133–145
  8. McCracken JT , McGough J , Shah B , et al.   Risperidone in children with autism and serious behavioral problems . N Engl J Med . 2002;347:314–321
  9. Turgay A , Binder C , Snyder R , Fisman S . Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs . Pediatrics . 2002;110:e34
  10. Snyder R , Turgay A , Aman M , et al.   Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs . J Am Acad Child Adolesc Psychiatry . 2002;41:1026–1036
  11. Haas M, Unis AS, Copenhaver M, Quiroz J, Kushner S, Kusumakar V. Efficacy and safety of risperidone in adolescents with schizophrenia. Poster presented at the American Psychiatric Association meeting, San Diego, May 19–24, 2007.
  12. Correll CU , Kane JM . One-year tardive dyskinesia rates in children and adolescents treated with second-generation antipsychotics: a systematic review . J Child Adolesc Psychopharmacol . 2007;17:647–655
  13. Kumra S , Frazier JA , Jacobsen LK , et al.   Childhood-onset schizophrenia: a double-blind clozapine-haloperidol comparison . Arch Gen Psychiatry . 1996;53:1090–1097
  14. Shaw P , Sporn A , Gogtay N , et al.   Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison . Arch Gen Psychiatry . 2006;63:721–730
  15. DelBello MP , Schwiers ML , Rosenberg HL , Strakowski SM . A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania . J Am Acad Child Adolesc Psychiatry . 2002;41:1216–1223
  16. Findling RA, Robb AS, Nyilas M, et al. Tolerability of aripiprazole in the treatment of adolescents with schizophrenia. Poster presented at the American Psychiatric Association meeting, San Diego, May 19–24, 2007.
  17. Barzman DH , DelBello MP , Kowatch RA , et al.   The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review . J Child Adolesc Psychopharmacol . 2004;14:593–600
  18. Campbell M , Armenteros JL , Malone RP , Adams PB , Eisenberg ZW , Overall JE . Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study . J Am Acad Child Adolesc Psychiatry . 1997;36:835–843
  19. Connor DF , Fletcher KE , Wood JS . Neuroleptic-related dyskinesias in children and adolescents . J Clin Psychiatry . 2001;62:967–974
  20. Malone RP , Maislin G , Choudhury MS , Gifford C , Delaney MA . Risperidone treatment in children and adolescents with autism: short-and long-term safety and effectiveness . J Am Acad Child Adolesc Psychiatry . 2002;41:140–147
  21. Research Units on Pediatric Psychopharmacology Autism Network  . Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months . Am J Psychiatry . 2005;162:1361–1369
  22. Correll CU , Leucht S , Kane JM . Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies . Am J Psychiatry . 2004;161:414–425
  23. Ananth J , Parameswaran S , Gunatilake S . Side effects of atypical antipsychotic drugs . Curr Pharm Des . 2004;10:2219–2229
  24. Patel NC , Hariparsad M , Matias-Akthar M , et al.   Body mass indexes and lipid profiles in hospitalized children and adolescents exposed to atypical antipsychotics . J Child Adolesc Psychopharmacol . 2007;17:303–311
  25. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity  . Consensus development conference on antipsychotic drugs and obesity and diabetes . J Clin Psychiatry . 2004;65:267–272
  26. Correll CU , Carlson HE . Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents . J Am Acad Child Adolesc Psychiatry . 2006;45:771–791
  27. Safer DJ . A comparison of risperidone-induced weight gain across the age span . J Clin Psychopharmacol . 2004;24:429–436
  28. Aman MG , Binder C , Turgay A . Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ . J Child Adolesc Psychopharmacol . 2004;14:243–254
  29. Correll CU . Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials . J Am Acad Child Adolesc Psychiatry . 2007;46:687–700
  30. Biederman J , Mick E , Hammerness P , et al.   Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children . Biol Psychiatry . 2005;58:589–594
  31. Martin A , L'Ecuyer S . Triglyceride, cholesterol and weight changes among risperidone-treated youths. A retrospective study . Eur Child Adolesc Psychiatry . 2002;11:129–133
  32. Blair J , Scahill L , State M , Martin A . Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study . J Am Acad Child Adolesc Psychiatry . 2005;44:73–79
  33. Glassman AH , Bigger JT . Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death . Am J Psychiatry . 2001;158:1774–1782
  34. Sallee FR , Kurlan R , Goetz CG , Singer H , et al.   Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study . J Am Acad Child Adolesc Psychiatry . 2000;39:292–299
  35. Silke B , Campbell C , King DJ . The potential cardiotoxicity of antipsychotic drugs as assessed by heart rate variability . J Psychopharmacol . 2002;16:355–360
  36. Wehmeier PM , Schuler-Springorum M , Heiser P , Remschmidt H . Chart review for potential features of myocarditis, pericarditis, and cardiomyopathy in children and adolescents treated with clozapine . J Child Adolesc Psychopharmacol . 2004;14:267–271
  37. Reyes M , Croonenberghs J , Augustyns I , Eerdekens M . Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: efficacy, safety, and tolerability . J Child Adolesc Psychopharmacol . 2006;16:260–272
  38. Croonenberghs J , Fegert JM , Findling RL , et al.   Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients . J Am Acad Child Adolesc Psychiatry . 2005;44:64–72
  39. Aman MG , Arnold LE , McDougle CJ , et al.   Acute and long-term safety and tolerability of risperidone in children with autism . J Child Adolesc Psychopharmacol . 2005;15:869–884
  40. Kumra S , Herion D , Jacobsen LK , Briguglia C , Grothe D . Case study: risperidone-induced hepatotoxicity in pediatric patients . J Am Acad Child Adolesc Psychiatry . 1997;36:701–705
  41. Gonzalez-Heydrich J , Raches D , Wilens TE , Leichtner A , Mezzacappa E . Retrospective study of hepatic enzyme elevations in children treated with olanzapine, divalproex, and their combination . J Am Acad Child Adolesc Psychiatry . 2003;42:1227–1233
  42. Gerbino-Rosen G , Roofeh D , Tompkins DA , et al.   Hematological adverse events in clozapine-treated children and adolescents . J Am Acad Child Adolesc Psychiatry . 2005;44:1024–1031
  43. Williams CL , Hayman LL , Daniels SR , et al.   Cardiovascular health in childhood: a statement for health professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young. American Heart Association . Circulation . 2004;106:143–160
  44. Lee JM , Okumura MJ , Davis MM , Herman WH , Gurney JG . Prevalence and determinants of insulin resistance among US adolescents: a population-based study . Diabetes Care . 2006;29:2427–2432
  45. Lee TJ , Safranek S . FPIN's clinical inquiries. A1C testing in the diagnosis of diabetes mellitus . Am Fam Physician . 2006;74:143–144
  46. Kryzhanovskaya L, Schulz CM, McDougle CJ, et al. Efficacy and safety of olanzapine in adolescents with schizophrenia: results from a double-blind, placebo-controlled trial. Poster presented at the 44th American College of Neuropsychopharmacology Meeting, Waikoloa, HI, December 1–15, 2005.
  47. Correll CU, Nyilas M, Aurang C, et al. Long term safety and tolerability of aripiprazole in children (10–17 y/o) with bipolar I disorder. Poster presented at the 54th annual meeting of the American Academy of Child and Adolescent Psychiatry, Boston, October 23–28, 2007.
  48. Robb AJ, Findling RL, Nyilas M, Forbes RA, McQuade RD, Mallikaarjun S, et al. Efficacy of aripiprazole in the treatment of adolescents with schizophrenia. Poster presented at the 160th annual meeting of the American Psychiatric Association, San Diego, May 19–24, 2007.
  49. Delbello MP, Findling RL, Earley WR, Acevedo LD, Stankowski J. Efficacy of quetiapine in children and adolescents with bipolar mania: a 3-week, double-blind, randomized, placebo-controlled trial. Poster presented at the 54th annual meeting of the American Academy of Child and Adolescent Psychiatry, Boston, October 23–28, 2007.
  50. Tohen M , Kryzhanovskaya L , Carlson G , Delbello M , Wozniak J , Kowatch R , et al.   Olanzepine versus placebo in the treatment of adolescents with bipolar mania . Am J Psychiatry . 2007;164:1547–1556
  51. Chang KD, Nyilas M, Aurang C, Johnson B, Jin N, Marcus R,et al Efficacy of aripiprazole in children (10–17 years old) with mania. Poster presented at the 54th annual meeting of the American Academy of Child and Adolescent Psychiatry, Boston, October 23–28, 2007.
  52. Pandina G, Delbello M, Kushner S, Van Hove I, Augustyns I, Kusumakar V, et al. Risperidone treatment of acute mania in bipolar youth. Poster presented at the 54th annual meeting of the American Academy of Child and Adolescent Psychiatry, Boston, October 23–28, 2007.
  53. Richelson E , Souder T . Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds . Life Sci . 2000;68:29–39
  54. Richelson E . Neuroleptic binding to human brain receptors: relation to clinical effects . Ann N Y Acad Sci . 1988;537:435–442
  55. Richelson E , Nelson A . Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro . Eur J Pharmacol . 1984;103:197–204
  56. Preskorn SH , Flockhart DA . 2006 guide to psychiatric drug interactions . Primary Psychiatry . 2006;13:35
  57. In:  Guy W editors. ECDEU Assessment Manual for Psychopharmacology: Publication ABM 76–338 . Washington, DC: US Department of Health, Education, and Welfare; 1976;p. 534–537
  58. Chouinard G , Ross-Chouinard A , Annabel L , Jones BD . The Extrapyramidal Symptom Rating Scale . Can J Neurol Sci . 1980;7:233
  59. Simpson GM , Angus JW . A rating scale for extrapyramidal side effects . Acta Psychiatr Scand Suppl . 1970;212:11–19
  60. Cook S , Weitzman M , Auinger P , Nguyen M , Dietz WH . Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988–1994 . Arch Pediatr Adolesc Med . 2003;157:821–827
  61. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults  . Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) . JAMA . 2001;285:2486–2497
  62. Fernandez JR , Redden DT , Pietrobelli A , Allison DB . Waist circumference percentiles in nationally representative samples of African-American, European-American, and Mexican-American children and adolescents . J Pediatr . 2004;145:439–444
  63. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents  . The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents . Pediatrics . 2004;114:555–576

 Assistant Editor's Note: Psychopharmacology Perspectives will bridge clinical and research expertise in pediatric psychopharmacology, with the goal of providing clinicians with practical clinical insights and up-to-date assessments of the evidence base. Authors will be invited to submit in-depth discussions of various topics in pediatric psychopharmacology, including experience-based practical guidance and the scientific rationale for treatment recommendations. Please feel free to contact me at ckratoch@unmc.edu if you have comments on this feature's revised format, or recommendations for future psychopharmacology topics of interest.

 Psychopharmacology Perspectives aims to discuss practical approaches to everyday issues in pediatric pharmacotherapy. The discussions may address aspects of clinical care related to psychopharmacology for which we do not have adequate applicable controlled trials. Given the need to address symptoms in youths with often complex, severe, and comorbid disorders, recommendations are likely to be off-label from the perspective of the U.S. Food and Drug Administration. We fully appreciate that for virtually all disorders, medication is only one aspect of comprehensive care. This column focuses primarily on psychopharmacological management. Although it is important that clinicians address psychosocial issues in the evaluation and treatment of their patients, such discussion is beyond the specific scope of this feature. These are not meant to be practice guidelines, but rather examples of the thought process that may go into pharmacotherapy decision making.

 Disclosure: Dr. Correll has been a consultant to AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Intra-Cellular Therapeutics, Organon, Otsuka, Pfizer, Solvay, Supernus, and Vanda, and has served on the speakers' bureaus/advisory boards of AstraZeneca, Bristol-Myers Squibb, Janssen, Eli Lilly, and Otsuka.

PII: S0890-8567(09)62080-3

doi: 10.1097/chi.0b013e31815b5cb1

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 47, Issue 1 , Pages 9-20 , January 2008

Article Tools